company background image
XXII

22nd Century Group NasdaqCM:XXII Stock Report

Last Price

US$2.05

Market Cap

US$440.2m

7D

22.8%

1Y

-44.1%

Updated

08 Aug, 2022

Data

Company Financials +
XXII fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

XXII Stock Overview

22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries.

22nd Century Group, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 22nd Century Group
Historical stock prices
Current Share PriceUS$2.05
52 Week HighUS$4.17
52 Week LowUS$1.42
Beta1.6
1 Month Change-5.09%
3 Month Change33.99%
1 Year Change-44.14%
3 Year Change8.47%
5 Year Change-4.21%
Change since IPO57.69%

Recent News & Updates

Aug 09

22nd Century GAAP EPS of -$0.06 in-line, revenue of $14.5M beats by $3.21M

22nd Century press release (NASDAQ:XXII): Q2 GAAP EPS of -$0.06 in-line. Revenue of $14.5M (+72.6% Y/Y) beats by $3.21M. The increase was due to increased contract manufacturing volumes as well as the addition of GVB Biopharma revenue for approximately half of the second quarter.

Jul 21

22nd Century Group launches $35M securities offering

22nd Century Group (NASDAQ:XXII) has announced a $35M share and warrant offering priced above market under Nasdaq rules. The offering will consist of 17,073,175 shares of common stock issued at $2.05/share. The company also agreed to offer unregistered warrants to purchase up to 17,073,175 shares of common stock; warrants are immediately exercisable at $2.05/share and will expire five years following the date of issuance. Gross proceeds are expected to be $35M; net proceeds will be used for expansion and expedite the launch of XXII's VLN reduced nicotine content tobacco cigarettes in additional markets, R&D expenses, procurement and development of additional IP rights, working capital and general corporate purposes. The proceeds will not be used to repay indebtedness or fund the operations of the company’s subsidiary, GVB Biopharma. Offering is expected to close on July 25, 2022.

Shareholder Returns

XXIIUS TobaccoUS Market
7D22.8%3.8%1.1%
1Y-44.1%-53.9%-13.0%

Return vs Industry: XXII exceeded the US Tobacco industry which returned -54% over the past year.

Return vs Market: XXII underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is XXII's price volatile compared to industry and market?
XXII volatility
XXII Average Weekly Movement15.4%
Tobacco Industry Average Movement15.4%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: XXII's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199876Jim Mishhttps://www.xxiicentury.com

22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications.

22nd Century Group, Inc. Fundamentals Summary

How do 22nd Century Group's earnings and revenue compare to its market cap?
XXII fundamental statistics
Market CapUS$440.21m
Earnings (TTM)-US$36.50m
Revenue (TTM)US$33.19m

13.3x

P/S Ratio

-12.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XXII income statement (TTM)
RevenueUS$33.19m
Cost of RevenueUS$31.31m
Gross ProfitUS$1.88m
Other ExpensesUS$38.38m
Earnings-US$36.50m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 09, 2022

Earnings per share (EPS)-0.17
Gross Margin5.67%
Net Profit Margin-109.97%
Debt/Equity Ratio0%

How did XXII perform over the long term?

See historical performance and comparison